Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Cullinan Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 103 | 106 | +3 |
| Shares | 32.3M | 36.9M | +4.62M (+14.3%) |
| Value | $329.5M | $397.3M | +$67.8M (+20.6%) |
New holders (23)
Institutions that held Cullinan Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (20)
Institutions that held Cullinan Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Silverarc Capital Management, LLC | 265,032 | $2.71M |
| EcoR1 Capital, LLC | 246,410 | $2.52M |
| Atom Investors LP | 120,109 | $1.23M |
| Ergoteles LLC | 48,622 | $497.4K |
| Wellington Management Group LLP | 27,122 | $277.5K |
| Tejara Capital Ltd | 23,600 | $241.4K |
| Squarepoint Ops LLC | 15,502 | $158.6K |
| CM Wealth Advisors LLC | 14,775 | $148.0K |
| HSBC Holdings PLC | 14,018 | $146.6K |
| State of Wisconsin Investment Board | 12,945 | $132.4K |
| Centiva Capital, LP | 12,497 | $127.8K |
| SG Americas Securities, LLC | 11,066 | $113.0K |
| Prelude Capital Management, LLC | 11,044 | $113.0K |
| Bailard, Inc. | 11,000 | $112.5K |
| Caxton Associates LP | 10,541 | $107.8K |
| US Bancorp | 1,084 | $11.1K |
| Envestnet Asset Management Inc | 55,170 | $5.39K |
| Signaturefd, LLC | 171 | $1.75K |
| Parallel Advisors, LLC | 36 | $368 |
| CWM, LLC | 23 | $0 |